Aptevo Therapeutics

APVO

Market cap $5.21M

APVO Hedge Fund Activity: Q1 2026 in Review

9 of the 8,150 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q1 2026, worth a combined $230K — up 20% from $191K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of APVO and 4 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $134K. The largest seller was Citigroup, exiting entirely with an estimated $26K sold.

• 9 institutional investors held Aptevo Therapeutics (APVO) as of Q1 2026, down from 11 in Q4 2025.
• Funds reported $230K of Aptevo Therapeutics stock for Q1 2026, up 20% quarter-over-quarter.
• 4 funds opened new Aptevo Therapeutics positions in Q1 2026 and 5 closed out, a net change of -1 holder.
• The largest Aptevo Therapeutics buyer in Q1 2026 was GSA Capital Partners, an estimated $134K added.
• The largest Aptevo Therapeutics seller in Q1 2026 was Citigroup, an estimated $26K sold.

Based on aggregated 13F filings for Q1 2026.